DE3514724A1 - Ointment for the prevention and treatment of disorders of the eyes and skin - Google Patents

Ointment for the prevention and treatment of disorders of the eyes and skin

Info

Publication number
DE3514724A1
DE3514724A1 DE19853514724 DE3514724A DE3514724A1 DE 3514724 A1 DE3514724 A1 DE 3514724A1 DE 19853514724 DE19853514724 DE 19853514724 DE 3514724 A DE3514724 A DE 3514724A DE 3514724 A1 DE3514724 A1 DE 3514724A1
Authority
DE
Germany
Prior art keywords
vitamin
ointment
treatment
skin
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19853514724
Other languages
German (de)
Other versions
DE3514724C2 (en
Inventor
Albin F. Dr. 4200 Oberhausen Jereb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19853514724 priority Critical patent/DE3514724A1/en
Publication of DE3514724A1 publication Critical patent/DE3514724A1/en
Application granted granted Critical
Publication of DE3514724C2 publication Critical patent/DE3514724C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

The ointment is intended to be used equally advantageously for disorders of the eyes and skin and for cosmetic purposes. Its composition for this purpose contains the following amounts of active substances relative to the ointment base: Vitamin A (Axeroptolum) 0.045% Vitamin B6 (Pyridoxin hydrochloridum) 0.025% Vitamin C (Acidum ascorbicum) 0.10% Vitamin D2 (Calciferolum) 0.015% Vitamin E (Tocopheroli acetas) 0.030% Vitamin K3 (Natrii menadion bisulfis) 0.005% Progesteron 0.005% Testosteron propionas 0.0025% Metholi 0.002% Sulfuri precipitati 0.015% Two bases suitable for the ointment are: Vaseline praecipi. pro oculi and/or Eucerinum cum aqua.

Description

Salbe zur Vorbeugung und Behandlung von Augen-Ointment for the prevention and treatment of eye

und Hauterkrankungen.and skin diseases.

Die Erfindung betrifft eine Salbe zur Vorbeugung und Behandlung von Augen- und Hauterkrankungen auf der Basis von Vitaminen der Gruppe A, B, D, E und K sowie der Hormone Progesteron und Testosteron in einer Salbengrundlage.The invention relates to an ointment for the prevention and treatment of Eye and skin diseases based on vitamins of group A, B, D, E and K as well as the hormones progesterone and testosterone in an ointment base.

Viele Hauskrankheiten werden durdifunktionelle Störungen der Talg- und Schweißdrüsen hervorgerufen wie beispielsweise die Acne vulgaris, Seborrhöe u.a.m.Many household diseases are caused by difunctional disorders of the sebum and sweat glands such as acne vulgaris, seborrhea u.a.m.

Zur Behandlung von Hautkrankheiten dienen Maßnahmen, die den Gesamtorganismus beeinflussen wie Diät, Umstimmung (z.B. Fieber), Vitamine, Hormone, Antibiotika und chemotherapeutische Mittel und örtliche Maßnahmen wie Umschläge, Puder, Pasten, Salben, Schüttelmixturen, Pinselungen mit Tinkturen, Anwendung verschiedener Strahlenarten (ultraviolett, Röntgen).For the treatment of skin diseases, measures serve the whole organism influence such as diet, change of mood (e.g. fever), vitamins, hormones, antibiotics and chemotherapeutic agents and local measures such as compresses, powders, pastes, Ointments, shaking mixtures, brushing with tinctures, application of various types of radiation (ultraviolet, X-ray).

Die erwähnten Behandlungsmethoden zeitigen oft nicht den gewünschten Erfolg oder bringen nur bei ganz bestimmten Hautkrankheiten Erfolge.The treatment methods mentioned often do not produce the desired results Success or only bring success with very specific skin diseases.

Es wurde bereits in der DE-OS 22 40 187 eine Heilsalbe für diegenannten Zwecke vorgeschlagen, die bei einer großen Anzahl von Hautkrankheiten Teilerfolge brachte.It was already in DE-OS 22 40 187 a healing ointment for those mentioned Proposed purposes that are partial successes in a large number of skin diseases brought.

Der Erfindung liegt die Aufgabe zugrunde, für diese einfache Salbenbehandlung eine wesentlich verbesserte Salbe vorzuschlagen, mit der sich sehr gute Erfolge bei Augen- und Hautkrankheiten erzielen lassen und die auch für kosmetische Zwecke einsetzbar ist.The invention is based on the object for this simple ointment treatment to propose a much improved ointment, with which very good results can be achieved in eye and skin diseases and also for cosmetic purposes can be used.

Gelöst wird diese Aufgabe nach dEr Erfindung durch eine Salbe, die folgende Wirkstoffmengen bezogen auf die Salbengrundlage enthält t Vitamin A (Ateroptoaum) 0,)45 so Vitamin B6 (Pyridoxin hydrochloridum) 0,25 %o Vitamin C (Acidim ascorbicum) 1,00 %o Vitamin D2 (Calciferolum) 0,15 %o Vitamin E (Tocopheroli acetas) 0,30 %o Vitamin K3 (Natrii menadion bisulfis) 0,05 %o Progesteron 0,05 so Testosteron propionas 0,025 %o Mentholi 0,02 so Sulfuri precipatati 0,15 %o.This object is achieved according to the invention by an ointment which The following amounts of active ingredients based on the ointment base contain t vitamin A (ateroptoaum) 0,) 45 so vitamin B6 (pyridoxine hydrochloridum) 0.25% o vitamin C (Acidim ascorbicum) 1.00% o Vitamin D2 (Calciferolum) 0.15% o Vitamin E (Tocopheroli acetas) 0.30% o Vitamin K3 (Natrii menadion bisulfis) 0.05% o progesterone 0.05 so testosterone propionas 0.025% o Mentholi 0.02 so Sulfuri precipatati 0.15% o.

Für die Salbe empfehlen sich die beiden Uundlagen: Vaseline praecipi. pro okuli und/eder Eucerinum cum aqua.For the ointment, we recommend the two bases: Vaseline praecipi. per okuli and / or Eucerinum cum aqua.

Eine derartige Salbe mit den oben beschriebenen Wirkstoffarten und Wirkstoffmengen ist vor allen Dingen geeignet für die Behandlung von Augenkrankheiten wie Konjunktivitis, Blepharitis, Hordeelom, Chalsion.Such an ointment with the types of active ingredients described above and Amount of active ingredient is particularly suitable for the treatment of eye diseases such as conjunctivitis, blepharitis, hordeeloma, chalsion.

Die Salbe erbringt aber auch deutliche Heilerfolge bei folgenden Hautkrankheiten : Akne vulgaris, Psoriasis vulgaris, Rosacea, Ekzemen, Furunkel, Pityriasis versicolor, Verruca (Warzen), Seborrhoe; Varikosis (Krampfadern).The ointment also has significant healing effects on the following skin diseases : Acne vulgaris, psoriasis vulgaris, rosacea, eczema, boils, pityriasis versicolor, Verruca (warts), seborrhea; Varicosis (varicose veins).

Ferner lassen sich Haemorrhoiden, Festulae, Pruritus ani Analfissurenrund Prellungen heilen.Furthermore, hemorrhoids, festulae, pruritus ani, anal fissures can be found Heal bruises.

Die Salbe ist aber auch zur Hautpflege bei SQmmersprossen, bei Atrophien.und Alterafalten geeignet.The ointment can also be used for skin care in case of sprouts, atrophy. And Suitable for altera wrinkles.

Sie kommt ferner für die Wundbehandlung, Ulcus cruris, Decubitus, Verbrennung und Sonnenbrand infrage.It is also used for wound treatment, leg ulcers, decubitus, Burn and sunburn in question.

Claims (2)

Patentansprfiche 1. Salbe zur Vorbeugung und Behandlung von Augen- und Hauterkrankungen auf der Basis von Vitaminen der Gruppe A,B,D,E und K sowie der Hormone Progesteron und Testosteron in einer Salbengrundlage, dadurch gekennzeichnet, daß sie folgende Wirkstoffmengen, bezogen auf die Salbengrundlage enthält Vitamin A (Axeroptolum) 0,45 so Vitamin B6 (Pyridoxin hydrochloridum) 0,25 %o Vitamin C (Acidum ascorbicum) 1,oo %o Vitamin D2 (Calciferolum) 0,15 %o Vitamin E (Tocopheroli acetas) 0,30 %o Vitamin K3 (Natrii menadion bisulfis) 0,05 %o Progesteron 0,05 %0 Testosteron propionas 0,025 %o Mentholi 0,02 so Sulfuri precipatati 0,15 %o.Claims 1. Ointment for the prevention and treatment of ocular and skin diseases based on vitamins of group A, B, D, E and K as well the hormones progesterone and testosterone in an ointment base, characterized that it contains the following amounts of active ingredient, based on the ointment base, vitamin A (Axeroptolum) 0.45 so vitamin B6 (pyridoxine hydrochloridum) 0.25% o vitamin C. (Acidum ascorbicum) 1, oo% o Vitamin D2 (Calciferolum) 0.15% o Vitamin E (Tocopheroli acetas) 0.30% o Vitamin K3 (Natrii menadion bisulfis) 0.05% o Progesterone 0.05% 0 Testosterone propionas 0.025% o Mentholi 0.02 so Sulfuri precipatati 0.15% o. 2. Salbe nach Anspruch 1, gekennzeichnet durch die zwei Grundlagen Vaseline praecipi. pro okuli und/oder Eucerinum cum aqua.2. Ointment according to claim 1, characterized by the two bases Vaseline praecipi. per okuli and / or Eucerinum cum aqua.
DE19853514724 1985-04-24 1985-04-24 Ointment for the prevention and treatment of disorders of the eyes and skin Granted DE3514724A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19853514724 DE3514724A1 (en) 1985-04-24 1985-04-24 Ointment for the prevention and treatment of disorders of the eyes and skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853514724 DE3514724A1 (en) 1985-04-24 1985-04-24 Ointment for the prevention and treatment of disorders of the eyes and skin

Publications (2)

Publication Number Publication Date
DE3514724A1 true DE3514724A1 (en) 1986-10-30
DE3514724C2 DE3514724C2 (en) 1989-10-26

Family

ID=6268943

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19853514724 Granted DE3514724A1 (en) 1985-04-24 1985-04-24 Ointment for the prevention and treatment of disorders of the eyes and skin

Country Status (1)

Country Link
DE (1) DE3514724A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0545759A1 (en) * 1991-11-28 1993-06-09 Société BFB Use of a sulfur containing amino acid, eventually in combination with pyridoxine, for the preparation of a medicament for the treatment of eczema
EP0727985A1 (en) * 1993-10-22 1996-08-28 Melvin L. Elson Composition and method for treating blood vessel disorders of the skin using vitamin k
DE19521684A1 (en) * 1994-07-26 1996-12-19 Kang Meng Che Ophthalmic pharmaceutical composition
FR2738743A1 (en) * 1995-09-19 1997-03-21 Oreal USE OF ASCORBIC ACID AS AN ACTIVE INGREDIENT FOR THE TREATMENT OF SEBORRHEA IN A COSMETIC AND / OR DERMATOLOGICAL COMPOSITION
EP0771555A2 (en) * 1994-08-03 1997-05-07 Goudzenko, Janna Prokophievna Agent for external application with nutrient and protective properties
EP0862916A1 (en) * 1995-11-20 1998-09-09 Kiyoshi Kita External preparation containing vitamin d or vitamin k
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
CN1054741C (en) * 1995-10-09 2000-07-26 康孟喆 Medicinal composite for eyes
EP1027045A1 (en) * 1997-10-31 2000-08-16 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
US6461622B2 (en) 1994-09-07 2002-10-08 Johnson & Johnson Consumer Companies, Inc. Topical compositions
US6531141B1 (en) 2000-03-07 2003-03-11 Ortho-Mcneil Pharmaceutical, Inc. Oil-in-water emulsion containing tretinoin
EP1433481A1 (en) * 2002-12-23 2004-06-30 Liang Youguo The use of methyltestosterone for the treatment of human papilloma virus infections
US6833141B1 (en) * 2003-07-11 2004-12-21 Joseph L. Owades Method of treating pruritis and composition thereof
USRE38813E1 (en) 1990-01-29 2005-10-04 Johnson & Johnson Consumer Companies, Inc. Retinoid compositions containing a water soluble antioxidant and a chelator
EP1594510A2 (en) * 2003-01-21 2005-11-16 Dimera Inc. Method and kit for reducing the symptoms of peripheral vascular disease
WO2009114745A1 (en) * 2008-03-13 2009-09-17 Hana Biosciences, Inc. Formulations of vitamin k analogs for topical use
EP2101785A2 (en) * 2006-12-05 2009-09-23 Southern College Of Optometry Treatment for dry eye
US7745494B2 (en) 2005-04-15 2010-06-29 Albert Einstein College Of Medicine Of Yeshiva University Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
WO2012103186A3 (en) * 2011-01-26 2012-09-20 Allergan, Inc. Androgen composition for treating an opthalmic condition
US9428582B2 (en) 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
US9458236B2 (en) 2001-06-13 2016-10-04 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090104C (en) † 1991-06-27 2002-05-28 Charles E. Clum Stabilized retinoid-containing skin care compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2240187A1 (en) * 1972-08-16 1974-02-21 Jereb Franz Dr Albin Vitamin/hormone ointment - esp for skin disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2240187A1 (en) * 1972-08-16 1974-02-21 Jereb Franz Dr Albin Vitamin/hormone ointment - esp for skin disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HELWIG: Moderne Arzneimittelwiss. Verlagsges. mbH, Stuttgart, 1980, S.1057 u. 1219 *
The-Merck-Index, 10.Ed. 1983, Nr.5662 u. 8858 *

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38813E1 (en) 1990-01-29 2005-10-04 Johnson & Johnson Consumer Companies, Inc. Retinoid compositions containing a water soluble antioxidant and a chelator
EP0545759A1 (en) * 1991-11-28 1993-06-09 Société BFB Use of a sulfur containing amino acid, eventually in combination with pyridoxine, for the preparation of a medicament for the treatment of eczema
EP0727985A1 (en) * 1993-10-22 1996-08-28 Melvin L. Elson Composition and method for treating blood vessel disorders of the skin using vitamin k
EP0727985A4 (en) * 1993-10-22 1997-07-02 Melvin L Elson Composition and method for treating blood vessel disorders of the skin using vitamin k
DE19521684A1 (en) * 1994-07-26 1996-12-19 Kang Meng Che Ophthalmic pharmaceutical composition
DE19521684C2 (en) * 1994-07-26 1999-09-02 Kang Pharmaceutical composition for ophthalmic use
EP0771555A4 (en) * 1994-08-03 1998-04-01 Zhanna Prokofievna Gudzenko Agent for external application with nutrient and protective properties
EP0771555A2 (en) * 1994-08-03 1997-05-07 Goudzenko, Janna Prokophievna Agent for external application with nutrient and protective properties
US6461622B2 (en) 1994-09-07 2002-10-08 Johnson & Johnson Consumer Companies, Inc. Topical compositions
EP0771557A1 (en) * 1995-09-19 1997-05-07 L'oreal Use of ascorbic acid as the actif for the treatment of seborrhea in a cosmetic and/or dermatalogical composition
JPH09110628A (en) * 1995-09-19 1997-04-28 L'oreal Sa Composition for make-up and/or dermatology containing ascorbic acid as active agent for treating seborrhea
FR2738743A1 (en) * 1995-09-19 1997-03-21 Oreal USE OF ASCORBIC ACID AS AN ACTIVE INGREDIENT FOR THE TREATMENT OF SEBORRHEA IN A COSMETIC AND / OR DERMATOLOGICAL COMPOSITION
CN1054741C (en) * 1995-10-09 2000-07-26 康孟喆 Medicinal composite for eyes
EP0862916A1 (en) * 1995-11-20 1998-09-09 Kiyoshi Kita External preparation containing vitamin d or vitamin k
EP0862916A4 (en) * 1995-11-20 2001-01-10 Kiyoshi Kita External preparation containing vitamin d or vitamin k
EP1027045A1 (en) * 1997-10-31 2000-08-16 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
EP1027045A4 (en) * 1997-10-31 2004-12-08 Arch Dev Corp Methods and compositions for regulation of 5-alpha reductase activity
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
US6531141B1 (en) 2000-03-07 2003-03-11 Ortho-Mcneil Pharmaceutical, Inc. Oil-in-water emulsion containing tretinoin
US9458236B2 (en) 2001-06-13 2016-10-04 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1433481A1 (en) * 2002-12-23 2004-06-30 Liang Youguo The use of methyltestosterone for the treatment of human papilloma virus infections
EP1594510A4 (en) * 2003-01-21 2008-07-23 Dimera Inc Method and kit for reducing the symptoms of peripheral vascular disease
US8182833B2 (en) 2003-01-21 2012-05-22 Dimera Incorporated Method and kit for reducing the symptoms of peripheral vascular disease with topical progesterone
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
US8420111B2 (en) 2003-01-21 2013-04-16 Dimera Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
EP1594510A2 (en) * 2003-01-21 2005-11-16 Dimera Inc. Method and kit for reducing the symptoms of peripheral vascular disease
US6833141B1 (en) * 2003-07-11 2004-12-21 Joseph L. Owades Method of treating pruritis and composition thereof
US8283382B2 (en) 2005-04-15 2012-10-09 Albert Einstein College Of Medicine Of Yeshiva University Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
US7745494B2 (en) 2005-04-15 2010-06-29 Albert Einstein College Of Medicine Of Yeshiva University Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
US9428582B2 (en) 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
EP2124958A2 (en) * 2006-12-05 2009-12-02 Southern College Of Optometry Treatment for dry eye using testosterone and progestagen
EP2101785A4 (en) * 2006-12-05 2009-12-30 Southern College Of Optometry Treatment for dry eye
EP2124958A4 (en) * 2006-12-05 2009-12-30 Southern College Of Optometry Treatment for dry eye using testosterone and progestagen
EP2101785A2 (en) * 2006-12-05 2009-09-23 Southern College Of Optometry Treatment for dry eye
WO2009114745A1 (en) * 2008-03-13 2009-09-17 Hana Biosciences, Inc. Formulations of vitamin k analogs for topical use
US8815953B2 (en) 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
US9119772B2 (en) 2011-01-26 2015-09-01 Allergan, Inc. Androgen composition for treating an opthalmic condition
WO2012103186A3 (en) * 2011-01-26 2012-09-20 Allergan, Inc. Androgen composition for treating an opthalmic condition
RU2599036C2 (en) * 2011-01-26 2016-10-10 Аллерган, Инк. Androgen composition for treating ophthalmic conditions
US9504646B2 (en) 2011-01-26 2016-11-29 Allergan, Inc. Androgen composition for treating an opthalmic condition
AU2012209184B2 (en) * 2011-01-26 2017-06-15 Allergan, Inc. Androgen composition for treating an opthalmic condition
US9937188B2 (en) 2011-01-26 2018-04-10 Allergan, Inc. Non-irritating testosterone emulsions
EP3388066A1 (en) * 2011-01-26 2018-10-17 Allergan, Inc. Androgen composition for treating an opthalmic condition
US10780098B2 (en) 2011-01-26 2020-09-22 Allergan, Inc. Non-irritating testosterone emulsions
US10905696B2 (en) 2011-01-26 2021-02-02 Allergan, Inc. Androgen composition for treating an ophthalmic condition

Also Published As

Publication number Publication date
DE3514724C2 (en) 1989-10-26

Similar Documents

Publication Publication Date Title
DE3514724A1 (en) Ointment for the prevention and treatment of disorders of the eyes and skin
AT406731B (en) SUBSTANCE MIXTURE FOR TOPICAL APPLICATION
DE2802924C2 (en) Medicines to treat acne
DE2046119A1 (en) Middle) to treat acne
DD277210A5 (en) THERAPEUTIC COMPOSITIONS AGAINST PSORIASIS
DE3836971C1 (en)
DE1902227A1 (en) Medicines for psychotherapeutic use and processes for their manufacture
DE2240187A1 (en) Vitamin/hormone ointment - esp for skin disorders
DE60027481T2 (en) Composition for the treatment of chronic venous insufficiency with an extract of leaves of red grapevines
EP0209724B1 (en) Preparation effective against acne and the use of an active extract of couch grass
EP0008052B1 (en) Anti-inflammatory and blood-stanching medicament
DE69927260T2 (en) TOPICAL PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SKIN OR CIRCULATORY DISEASES OF INFLAMMATORY, IMMUNE, PROLIFERATIVE OR DEGENERATIVE BASIS
EP1131063B1 (en) Hyperforin ointment or cream
EP0198172B1 (en) Pharmaceutical preparation
CN1054291C (en) Compound for curing spur and cervical spondylopathy and its application in plaster
EP0668768B1 (en) Composition for controlling dermatomycoses and their agents, as well as transpiration and bodily odours
DE4300969C2 (en) Use of Malotilat to accelerate wound healing in case of skin burns
EP0273407A2 (en) Medicine for improving the specific properties of blood
DE202004012348U1 (en) Composition for skin care in cases of psoriasis or eczema comprises an acidic mixture of onion or garlic, an organic acid and other natural ingredients
DE2934090A1 (en) Agent for treating hyper:keratotic skin diseases - contains undecylenic acid pref. in combination with ascorbic acid
DE2460205A1 (en) Anti-dermatomycosis medicaments - contg hinokitiol, undecylic acid, and thymol
DE2620852A1 (en) MEDICINAL PRODUCTS FOR THE TREATMENT OF ALOPECIA AREATA
DE4110134A1 (en) Cosmetic and/or pharmaceutical compsn. contg. banana skin - for external application to skin, esp. to treat warts and other skin disorders
EP3741378A1 (en) Topical composition for the treatment and care of psoriatic skin
DE202005007462U1 (en) Medicament or nutritional supplement composition, for combating chronic viral infections, containing vitamin C, vitamin E, coenzyme Q10, carotenoids, selenium, zinc and copper

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee